Health software leader equips client with technology to empower development of emerging therapies through Leukopacks and assist with testing at immunohematology reference labs
OVERLAND PARK, Kan.--(BUSINESS WIRE)--WellSky, a global health and community care technology company, today announced that it will deliver the American Red Cross a range of new technology solutions to support the development by the Red Cross of specialty blood products and complex testing. WellSky technology solutions — including WellSky Biotherapies Lab, WellSky Scheduling, and WellSky Transfusion — will be used at the organization’s eight Leukopack collection sites and 45 immunohematology reference laboratories (IRLs) to enhance blood product availability for patient transfusions and to advance research into new cell therapy treatments.
WellSky will assist the Red Cross with their research into innovative new biotherapies through the collection of Leukopacks, which are enriched blood products collected from normal peripheral blood apheresis donations that have the potential to treat patients with cancer and other chronic health conditions.
“As a humanitarian organization dedicated to alleviating suffering, the Red Cross supports research in specialty blood products as part of our mission,” said John Mass, vice president of business systems integration for Red Cross Biomedical Services. “WellSky Biotherapies Lab will help us identify and engage donors with the right cellular profile to assist in this important research process for future therapeutic interventions.”
WellSky Transfusion technology will be used during the Red Cross specialty testing at immunohematology reference labs, serving hospitals and their patients. WellSky technology will help standardize testing across the 45 Red Cross IRL locations.
“Our work with the Red Cross illustrates exactly what we mean when we talk about WellSky’s mission of realizing care’s potential,” said Bill Miller, CEO of WellSky. “We’ve seen the life-changing and life-saving services the Red Cross provides on a daily basis, and now we’re honored to support its research into leading-edge treatments that can transform care as we know it. This is the type of visionary thinking that accelerates us into the future of healthcare.”
WellSky is committed to supporting the Red Cross as the organization continues to serve people and communities across the U.S., all while contending with the ongoing COVID-19 pandemic, and its effects on blood supply and demand. Recognizing that a range of factors are impacting the work of the Red Cross, WellSky will deliver advanced technology that fits the organization’s complex requirements, supports higher volumes for specialized products, and can be implemented on an expedited timeline to ensure continuity.
WellSky is a technology company advancing human wellness worldwide. Our software and professional services address the continuum of health and social care — helping businesses, organizations, and communities solve tough challenges, improve collaboration for growth, and achieve better outcomes through predictive insights that only WellSky solutions can provide. WellSky is leading the movement for smarter, whole-person care with a visionary approach that addresses individuals’ unique health and social circumstances. WellSky serves more than 15,000 client sites around the world — including the largest hospital systems, blood banks and labs, blood centers, home health and hospice franchises, government agencies, and human services organizations. Informed by 40 years of providing software and expertise, WellSky anticipates providers’ needs and innovates relentlessly to help people thrive. Our purpose is to empower care heroes with technology for good, so that together, we can realize care’s potential and maintain a healthy, flourishing world. For more information, visit WellSky.com.